English 日本語

#AstellasPharmaInc

List of IR information related to "AstellasPharmaInc".

1 IR Posts
1 Companies
29 days ago Last Updated

Filters

Reset
Period:
Importance:
1 IR Posts
4503 Astellas Pharma Inc.
2025/12/18
Antibody-Drug Conjugate PADCEV TM (Enfortumab Vedotin) Shows Favorable Results in Phase III EV-304 Trial for Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Astellas Pharma announced that the combination therapy of PADCEV (Enfortumab Vedotin) and Pembrolizumab improved event-free survival and overall survival in cisplatin-eligible muscle-invasive bladder cancer in the Phase III EV-304 trial.

Strategy/Investment,Other
#AstellasPharmaInc #NewProduct #JapaneseStocks
Scroll to Top